
Fulcrum’s Losmapimod: Potential Aid, But Its Ability To Modify FSHD Is Uncertain (FULC)
Ivan Mattioli/iStock via Getty Images Introduction Fulcrum Therapeutics (NASDAQ:FULC) is a biopharmaceutical company that specializes in the development of innovative therapies for the treatment of genetic diseases. One of the company’s most promising experimental drugs […]